ABBVIE said Health Canada has issued a Notice of Compliance with Conditions for Venclexta (venetoclax). The therapy has been approved for previously treated chronic lymphocytic leukemia patients, who have either a genetic mutation, known as 17p deletion, or no other available treatment options. Under NOC/c policy, AbbVie will provide Health Canada with data from additional...
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
